China IVD Risk Classification Explained: How NMPA Class Shapes Registration Pathways

China IVD risk classification is the first and most consequential regulatory decision foreign manufacturers face when bringing an in vitro diagnostic product to the China market. Established before any registration dossier is submitted, this classification determines how the NMPA evaluates a diagnostic product, shaping approval pathways, performance evaluation and clinical evidence requirements, review timelines, and long-term compliance obligations.

Continue below for the full explainer or get in touch with Cisema for support in confirming your China IVD classification and aligning your NMPA registration strategy.

What Is China IVD Classification Under NMPA Regulations?

China regulates in vitro diagnostic products through a risk-based classification system established under the Classification Rules for In Vitro Diagnostic Reagents and administered by the National Medical Products Administration (NMPA). This framework governs how IVDs are reviewed, approved, and managed throughout their lifecycle in China.

The system is implemented through 2 parallel, legally binding classification catalogues, which must be assessed independently even when products are intended to function together:

• Medical Device Classification Catalogue: IVD instruments, such as analyzers and testing platforms (read our China Medical Device Risk Classification Guide for a detailed explanation of how China classifies non-diagnostic medical devices)
• In Vitro Diagnostic Reagent Classification Catalogue: IVD reagents, including test kits, calibrators, and controls

Together, these catalogues assign each product to a regulatory class based on intended use, test methodology, target population, and the potential impact of test results on clinical decision-making and public health.

China IVD Risk Classes Explained (Class I – Class III)

China assigns all IVD products to 3 regulatory classes: Class I, Class II, and Class III. Each class reflects a defined increase in diagnostic risk, regulatory scrutiny, and lifecycle compliance responsibility.

While China’s approach follows a risk-based regulatory philosophy, its IVD classification structure differs from the A–D system used under the EU’s IVDR 2017/746 Annex VIII. In China, regulatory control increases progressively across Class I–III as the clinical and public health impact of diagnostic results increases.

Unlike general medical devices, which are often classified based on physical interaction with the body, IVDs influence patient care indirectly through diagnostic information. As a result, China’s IVD classification focuses on the consequences of test results rather than physical invasiveness.

Key considerations include:

• The intended use and clinical role of the test
• The level of professional judgment required to interpret results
• The potential impact of incorrect results on diagnosis, treatment decisions, or public health

With this framework in place, the regulatory expectations associated with each China IVD class can now be examined in practical terms.

Class I IVD Medical Devices in China (Low Risk)

Class I IVDs present minimal diagnostic risk and do not directly influence clinical decision-making or treatment selection. These products typically support specimen collection, preparation, or basic laboratory identification with limited consequence if results are inaccurate.

Common Class I IVD examples include:

• Specimen collection products: Items used only to collect or hold samples, such as plain urine containers
• Non-diagnostic culture and identification materials: Products for growing or handling non-pathogenic microorganisms or cells, where there is no diagnostic, identification, or drug sensitivity claim
• Sample preparation and processing reagents: Reagents used to prepare samples for testing, including diluents, staining solutions, hemolyzing agents, and nucleic acid extraction or purification reagents
• General-purpose laboratory reagents: Buffers, substrates, enhancer solutions, and stabilizers that support reaction systems but do not determine or interpret test results

Typical regulatory characteristics include simplified record-filing procedures, limited performance verification requirements, and no clinical trial expectations.

Class II IVD Medical Devices in China (Moderate Risk)

Class II IVDs support routine clinical assessments and screening activities. While inaccurate results may influence medical judgment, they are unlikely to result in immediate or irreversible patient harm when used appropriately.

Compared to Class I products, Class II IVDs require more structured technical documentation and closer alignment with applicable China IVD technical standards.

Representative Class II IVD categories and examples include:

• Biochemical and metabolic detection reagents: Liver function reagents, electrolyte testing reagents, metabolic screening kits
• Hormone detection reagents: Pregnancy test reagents, thyroid hormone testing reagents
• Immune function and autoantibody detection reagents: Allergen screening reagents, autoimmune screening assays
• Drug and drug metabolite detection reagents: Therapeutic drug monitoring reagents, drug compliance screening tests
• Microbial identification and drug sensitivity reagents: Culture-based identification reagents, antimicrobial susceptibility test kits
• Cell culture media for IVD use: Specialized diagnostic cell culture media

Class III IVD Medical Devices in China (High Diagnostic Impact)

Class III IVDs play a critical role in disease diagnosis, screening programs, or ongoing disease management. Incorrect results at this level can materially affect patient outcomes or public health monitoring, resulting in the highest level of regulatory scrutiny.

Representative Class III IVD categories include:

• Pathogen detection reagents: Assays detecting antigens, antibodies, or nucleic acids of infectious pathogens
• Blood typing and tissue typing reagents: ABO/Rh blood group typing reagents, HLA tissue typing assays
• Human genetic testing reagents: Genetic screening assays for inherited traits or predispositions
• Genetic disease detection reagents: Diagnostic tests for inherited or congenital genetic disorders
• Narcotic, psychotropic, and toxic drug detection reagents: Detection assays for controlled substances or toxic medicinal compounds
• Therapeutic drug target and companion diagnostic reagents: Biomarker assays guiding targeted therapy selection
• Tumor screening and diagnostic reagents: Cancer screening, diagnostic, auxiliary diagnostic, or disease staging assays

Foreign manufacturers frequently underestimate the scrutiny applied to Class III IVD claims, particularly for home-use products, where user comprehension, labeling clarity, and risk mitigation measures are closely reviewed.

What Falls Outside China’s IVD Regulatory Scope?

Not all laboratory or diagnostic-related products are regulated as IVD medical devices, even if their use appears similar. Under China’s framework, certain products are explicitly excluded from IVD classification and regulated under separate regimes, including:

• In vitro diagnostic reagents used for blood screening or labeled with radioactive nuclides, which are regulated as pharmaceuticals rather than medical devices
• Cell culture media intended for cell therapy, cell infusion, assisted reproduction, or related applications, which fall outside the IVD definition due to their therapeutic or biological function

Common China IVD Classification Mistakes and How to Avoid Them

Delays in China IVD registration are rarely caused by diagnostic risk alone. More often, they result from avoidable errors made during early classification and regulatory planning. These missteps frequently lead to extended review timelines, additional evidence requests, and unplanned resubmissions for foreign manufacturers.

By understanding where IVD classification commonly goes wrong, companies can reduce uncertainty and align their China registration strategy from the outset.

Misinterpreting Classification Drivers: Intended Use, Claims, and Features

A common mistake is assuming that China IVD classification is determined by assay type, product name, or similarity to existing catalogue entries. In practice, classification is driven by intended use, clinical application, target population, and the potential impact of test results on diagnosis, treatment decisions, or public health.

Even limited claim changes — such as adding screening language, expanding indications, enabling quantitative interpretation, or introducing home use — can elevate an IVD into a higher risk class, despite no change in underlying technology.

Foreign manufacturers should complete a structured intended-use and claims review before finalizing classification. Early alignment of labeling, instructions for use, software logic, and result interpretation helps prevent reclassification during NMPA review.

Assuming Global IVD Approvals Translate Directly to China

Many manufacturers expect China IVD requirements to closely follow EU IVDR or U.S. FDA pathways. While global approvals are useful references, China applies its own classification logic, performance evaluation standards, and review expectations.

This often leads to underestimated timelines and budgets, particularly for Class II and Class III IVDs. Classification should therefore be reassessed independently under NMPA rules, with planning that allows for extended reviews and additional evidence.

Treating IVD Classification as a One-Time Task Instead of a Lifecycle Commitment

The relevance of IVD classification in China extends beyond initial approval. The assigned class determines how product changes, labeling updates, software revisions, indication expansions, and renewals are regulated.

Treating classification as a one-time step often creates compliance issues post-approval. Establishing change management procedures aligned with the approved IVD classification supports long-term compliance and portfolio stability in China.

China IVD Classification: Key Takeaways

China’s IVD risk classification framework underpins every stage of NMPA review, from initial registration through post-approval changes and renewals. For foreign manufacturers, getting this classification right at the outset is critical. An incorrect or poorly supported IVD class can quickly lead to misaligned submission strategies, additional evidence requests, and avoidable delays to market entry.

With more than 20 years of regulatory experience in China, Cisema works alongside foreign manufacturers to confirm IVD classification, define NMPA registration pathways, and support long-term compliance across the diagnostic product lifecycle. For IVD companies seeking a predictable and defensible route to the China market, get in touch with Cisema to move forward with clarity and confidence.

Further Information

• Learn more about Cisema’s Medical Device/IVD Consulting and Registration Services in China, including support with NMPA IVD classification confirmation, registration strategy, and ongoing lifecycle compliance.
• Explore Cisema’s Medical Device/IVD Registration Services Across Asia Pacific, covering approval pathways in Hong Kong, Taiwan, and key Southeast Asian markets.
• Read our China Medical Device Risk Classification Guide for an explanation of how China classifies general medical devices under NMPA regulations.

References

• Read the Rules for Classification of Medical Devices (Decree No. 15 of the China Food and Drug Administration) (English)
• Refer to the Medical Device Classification Catalogue (医疗器械分类目录) issued by the National Medical Products Administration (Chinese)
• Refer to the In Vitro Diagnostic Reagent Classification Catalogue (体外诊断试剂分类目录) issued by the National Medical Products Administration (Chinese)) issued by the National Medical Products Administration (Chinese)
• Refer to the Classification Rules for In Vitro Diagnostic Reagents (体外诊断试剂分类规则) issued by the National Medical Products Administration (Chinese)

Frequently Asked Questions About China IVD Risk Classification

How Is IVD Risk Classification Determined in China? China IVD risk classification is determined by matching the product’s intended use, claims, test principle, target analyte, and diagnostic impact against the NMPA In Vitro Diagnostic Reagent Classification Catalogue.
If no exact catalogue entry applies, classification must be justified using the IVD Classification Rules, supported by technical rationale and risk analysis. Both IVD reagents and IVD instruments must be assessed independently under their respective catalogues.

What Happens If an IVD Is Misclassified in China? If an IVD is submitted under an incorrect risk class, the NMPA may suspend technical review and require resubmission under the correct classification.
Misclassification often results in additional testing, expanded performance evaluation requirements, and significant approval delays. Early classification confirmation is therefore critical to avoid rework and extended timelines.

Does a Higher IVD Risk Class Mean a Longer Approval Timeline in China? Yes. Higher IVD risk classes are subject to more extensive technical review, stricter performance evaluation requirements, and longer NMPA review timelines.

Are Clinical Trials Required for Class III IVDs in China? Clinical performance evaluation is required for all Class III IVDs. Clinical trials may be required unless the product is listed in the NMPA IVD Clinical Trial Exemption Catalogue or sufficient alternative evidence is accepted by regulators.
Whether a trial is required depends on the product’s intended use, diagnostic risk, novelty, and available supporting data.

Are IVD Instruments and IVD Reagents Classified Separately in China? Yes. IVD instruments and IVD reagents are classified under separate NMPA catalogues and must be evaluated independently, even when they are designed to be used together as a system.
Failing to assess instrument and reagent classification separately is a common cause of regulatory delay and additional submissions.